Trade Summary

4 months ago, Kewalramani Reshma, serving as CEO, Pres at Vertex Pharmaceuticals Inc / Ma (VRTX), purchased 10,000 shares at $389.58 per share, for a total transaction value of $3,895,768.00. Following this transaction, Kewalramani Reshma now holds 115,968 shares of VRTX.

This purchase represents a 9.00% increase in Kewalramani Reshma's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, August 6, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, August 7, 2025, 1 day after the trade was made.

Vertex Pharmaceuticals Inc / Ma operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.